Version history

{
  "session_id": "sess_sda-2026-04-12-ev-ad-biomarkers_20260412-082939",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: EV-Derived Biomarkers for Early/Prodromal AD\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Tier 1: NDEV p-Tau Species (Strongest, but requires precision correction)\n\nNDEV-derived phospho-tau remains the most translationally advanced EV concept, but the current framing conflates evidence across epitopes in ways that would undermine credibility with regulatory reviewers or clinical collaborators. The p-tau231 hypothesis is mechanistically interesting but the evidentiary base is substantially weaker than for p-tau181. If pursued, it must be presented as a next-generation hypothesis building on p-tau181, not as independently validated.\n\n### Tier 2: NDEV Synaptic Proteins (Most differentiated from plasma assays)\n\nGAP-43, neurogranin, and synaptotagmin-",
  "tokens_used": "200"
}